XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
9 Months Ended
Sep. 30, 2025
Segment Reporting  
Segment Reporting

14. Segment Reporting

The Company operates as a single operating segment. Its operations consist of developing and commercializing innovative therapies for retinal diseases and other eye conditions based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology.

Resources are allocated and performance is assessed by the Company’s Chief Executive Officer and the Company’s Chief Financial Officer and Chief Operating Officer, who the Company has determined to be, collectively, the Company’s Chief Operating Decision Maker (“CODM”).

The accounting policies for the Company’s one segment are the same as those described in Note 2. The CODM evaluates the performance of its one segment and allocates resources based on Net Loss.

The following table provides information about the Company’s single segment:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2025

    

2024

    

2025

    

2024

Revenue

$

14,544

$

15,425

$

38,701

$

46,641

Cost of product revenue

1,774

1,561

4,980

4,396

Research and development (a)

Direct program expenses

AXPAXLI for wet AMD

34,707

17,017

92,893

35,263

Other clinical and preclinical programs

1,224

1,184

3,307

6,750

Unallocated expenses

Personnel costs

9,136

7,551

27,825

22,168

All other costs

1,632

6,365

5,986

8,815

Selling and marketing (a)

11,721

9,601

36,972

27,997

General and administrative (a)

8,563

8,832

26,864

28,294

Facilities (b)

1,722

1,713

5,230

5,416

Stock-based compensation

11,691

6,641

31,825

25,912

Depreciation

1,072

958

3,076

2,835

Interest income

3,729

5,653

11,012

15,611

Interest expense

(3,002)

(3,224)

(9,003)

(10,471)

Loss from debt extinguishment

(27,950)

Other non-operating items

(1,447)

7,076

(3,037)

(1,103)

Net loss

$

(69,418)

$

(36,493)

$

(201,285)

$

(145,118)

(a)excluding stock-based compensation, depreciation, and facilities expenses
(b)excluding stock-based compensation and depreciation